G1 THERAPEUTICS (GTHX) Receiving Somewhat Positive Press Coverage, Accern Reports
News headlines about G1 THERAPEUTICS (NASDAQ:GTHX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. G1 THERAPEUTICS earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.3328588907792 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of equities analysts have issued reports on GTHX shares. J P Morgan Chase & Co started coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They set an “overweight” rating and a $23.00 price target on the stock. Cowen and Company started coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They set an “outperform” rating and a $31.00 price target on the stock. Needham & Company LLC started coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They set a “buy” rating and a $34.00 price target on the stock. Finally, Wedbush started coverage on G1 THERAPEUTICS in a research report on Monday, June 12th. They set an “outperform” rating and a $31.00 price target on the stock.
G1 THERAPEUTICS (NASDAQ:GTHX) opened at 24.77 on Tuesday. The stock’s market cap is $700.62 million. The firm’s 50-day moving average price is $18.33 and its 200-day moving average price is $17.43. G1 THERAPEUTICS has a 12 month low of $12.04 and a 12 month high of $28.67.
G1 THERAPEUTICS (NASDAQ:GTHX) last released its earnings results on Wednesday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.48). On average, analysts predict that G1 THERAPEUTICS will post ($2.92) earnings per share for the current year.
G1 THERAPEUTICS Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Stock Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related stocks with our FREE daily email newsletter.